AI driven oncology Leverage Lantern Pharma's RADR AI platform and recent launches like zetaomics and ZetaSwarm to position advanced AI-driven drug discovery and clinical trial design services to biopharma partners seeking faster, data-informed oncology programs.

Pediatric CNS focus Target partnerships around STAR-001 for pediatric CNS tumors, highlighting FDA IND clearance and phase 1 trial readiness as a proof point for collaboration on safe, targeted pediatric oncology therapies.

Global expansion Capitalize on the India AI Center of Excellence and regional expansion to offer cost-efficient, globally coordinated research partnerships, clinical trial support, and data analytics services across Asia and beyond.

Precision oncology demand Position Lantern as a partner for biomarker-driven trial design and patient stratification, emphasizing the ability to identify responders and optimize trial outcomes through RADR-enabled genomics insights.

Strategic collaboration Highlight opportunities to co-develop or license novel mechanisms and drug repurposing strategies, using Lantern’s capabilities to revitalize abandoned assets and accelerate time-to-value for oncology programs.